( April 1, 2025, 12:01 PM EDT) -- WASHINGTON, D.C. — A Federal Circuit U.S. Court of Appeals panel said a New Jersey federal judge was right to conclude after a bench trial that a biopharmaceutical company’s antipsychotic medication product would induce health care providers to infringe on another company’s patented injectable medication used to treat schizophrenia....